Sandoz Reveals Aflibercept Program

Kicks Off Phase III Trials For Biosimilar Version Of Eylea

 
• By David Wallace
  
Eye Scan Data
Sandoz is enrolling patients for an aflibercept trial • Source: Alamy
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products